Prognostic value of multidrug resistance 1, glutathione-S-transferase-π and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy

Oncology

Volumn 62, Issue 4, 2002, Pages 305-312

  Hsu, Chih Hung ^a,c   Chen, Chi Long ^a,b   Hong, Ruey Long ^a,c   Chen, Kai Lii ^a,c   Lin, Jing Fan ^a,c   Cheng, Ann Lii ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chemoresistance; Glutathione S transferase ; Multidrug resistance 1; Nasopharyngeal carcinoma; p53

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53;

ADULT; AGED; ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CHEMOSENSITIVITY; CHINA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MULTIDRUG RESISTANCE; NASOPHARYNX CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; TAIWAN;

EID: 0036060382     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065061     Document Type: Article

References (60)

1. Epidemiological characteristics and early detection of nasopharyngeal carcinoma in Taiwan. Head neck oncology research
2. Nasopharyngeal cancer: Epidemiology, staging, and treatment
3. Nasopharyngeal carcinoma: The Epstein-Barr virus association
4. Undifferentiated nasopharyngeal cancer (UCNT): Current diagnostic and therapeutic aspects
5. Chemotherapy with cisplatin and continuous infusion of 5-fluororacil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan
6. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin, using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma
7. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: A phase II study
8. The role of chemotherapy in the management of nasopharyngeal carcinoma
9. Multidrug resistance mediated by p-glycoproteins
10. p-glycoprotein - A mediator of multidrug resistance in tumour cells
11. Glutathione and related enzymes in multidrug resistance
12. Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines
13. Expression of p-glycoprotein and glutathione-s-transferase in recurrent lymphoma: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors
14. Immunohistochemical expression of glutathione S-transferase-pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma
15. p53: The cellular gatekeeper for growth and division
16. The p53 tumor suppressor gene
17. Apoptosis and chemotherapy resistance
18. Apoptosis in cancer therapy: Crossing the threshold
19. p53-dependent apoptosis modulated the cytotoxicity of anticancer agents
20. Cancer therapy and p53
21. Clinical implications of the p53 tumour suppressor gene
22. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer
23. p53 expression and poor prognosis in childhood acute lymphoblastic leukemia
24. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
25. p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time
26. Prognostic value of p53, glutathione S-transferaseπ, and thimydylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer
27. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
28. p-glycoprotein in adult solid tumors: Expression and prognostic significance
29. p-glycoprotein in adult hematologic malignancies
30. Clinical significance of p-glycoprotein in multidrug resistance malignancies
31. Immunohistochemical detection of p-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood
32. p-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
33. Clinical relevance of immunohistochemical detection of multidrug resistance p-glycoprotein in breast carcinoma
34. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
35. Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response
36. Immunohistochemically detected p53 and p-glycoprotein predicts the response of chemotherapy in lung cancer
37. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
38. Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers
39. p-glycoprotein - A marker of cancer cell behavior
40. Clinical multidrug resistance in cancer: A multifactorial problem
41. Relationship of the expression of the multidrug resistance gene product (p-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis
42. Expression of multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage
43. Multidrug resistance in breast cancer: Mechanisms, strategies
44. Implications of the p53 tumor-suppressor gene in clinical oncology
45. p53 and response to chemotherapy and radiotherapy
46. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
47. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study
48. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer
49. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum
50. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas
51. Drug resistance and sensitivity of germ cell testicular tumors: Evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins
52. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors
53. Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia
54. p53 mutation in human nasopharyngeal carcinomas
55. p53 inactivation mutations in Chinese nasopharyngeal carcinomas
56. Assessment of p53 expression in nasopharyngeal carcinoma
57. Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma
58. p53 and chemosensitivity
59. Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy
60. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression